Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05CEO
|
||||
| Former ID |
DNCL003320
|
||||
| Drug Name |
Brodalumab
|
||||
| Synonyms |
AMG 827
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Severe plaque psoriasis [ICD10:L40] | Approved | [1] | ||
| Psoriasis [ICD9: 696; ICD10:L40] | Phase 3 | [2], [3] | |||
| Asthma [ICD10:J45] | Phase 2 | [3], [4] | |||
| Company |
Valeant Luxembourg
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-17 | Target Info | Modulator | [5] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| IL23-mediated signaling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| Allograft Rejection | |||||
| IL17 signaling pathway | |||||
| References | |||||
| REF 1 | Drugs@FDA (Edaravone) | ||||
| REF 2 | ClinicalTrials.gov (NCT02029495) Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis. U.S. National Institutes of Health. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7540). | ||||
| REF 4 | Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis | ||||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.